The prognostic significance of NPM1, particularly in conjunction with co-occurring mutations such as FLT3-ITD and myelodysplasia-related gene signature (AML-MR), has become increasingly central to risk stratification, as reflected in the 2022 European LeukemiaNet (ELN) guidelines [3,4,5]. The gene discussed is FLT3; the disease is acute myeloid leukemia.